Teva Pharmaceutical Industries (NYSE:TEVA) Stock Bumped Up to “Hold” by Zacks Research

Zacks Research upgraded shares of Teva Pharmaceutical Industries (NYSE:TEVA – Free Report) from a strong sell rating to a hold rating in a report published on Wednesday,Zacks reports.

Several other equities research analysts have also recently issued reports on TEVA. Weiss Ratings upgraded Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, November 4th. Piper Sandler increased their target price on Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a report on Thursday, November 12th. JPMorgan Chase & Co. boosted their target price on shares of Teva Pharmaceutical Industries from $40.00 to $50.00 and gave the company an “overweight” rating in a research report on Monday, October 12th. TD Cowen upped their price target on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a report on Wednesday, November 4th. Finally, Barclays increased their price target on shares of Teva Pharmaceutical Industries from $47.00 to $50.00 and gave the stock an “overweight” rating in a research report on Thursday. Fourteen investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $48.64.

Check Out Our Latest Research Report on TEVA

Teva Pharmaceutical Industries Price Performance

NYSE:TEVA opened at $38.53 on Wednesday. Teva Pharmaceutical Industries has a 52 week low of $24.01 and a 52 week high of $44.57. The company has a debt-to-equity ratio of 1.59, a quick ratio of 0.74 and a current ratio of 0.95. The firm’s 50-day simple moving average is $40.56 and its 200 day simple moving average is $35.22. The firm has a market cap of $44.90 billion, a price-to-earnings ratio of 89.61, a P/E/G ratio of 3.66 and a beta of 0.97.

Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) last posted its quarterly earnings data on Tuesday, November 3rd. The company reported $0.86 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a net margin of 2.94% and a return on equity of 33.20%. The firm had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the firm posted $0.78 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, sell-side analysts predict that Teva Pharmaceutical Industries will post 1.98 earnings per share for the current year.

Insider Activity at Teva Pharmaceutical Industries

In related news, CEO Richard Francis sold 250,000 shares of the company’s stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the completion of the sale, the chief executive officer directly owned 927,529 shares in the company, valued at $39,178,824.96. This represents a 21.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Roberto Mignone sold 367,600 shares of the firm’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $39.06, for a total value of $14,358,456.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 715,945 shares of company stock worth $29,061,351 in the last three months. Insiders own 0.54% of the company’s stock.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently made changes to their positions in TEVA. Marshall Wace LLP acquired a new position in Teva Pharmaceutical Industries during the 3rd quarter worth approximately $110,197,000. Assenagon Asset Management S.A. lifted its stake in Teva Pharmaceutical Industries by 128.1% in the 2nd quarter. Assenagon Asset Management S.A. now owns 3,056,017 shares of the company’s stock valued at $103,538,000 after purchasing an additional 1,716,315 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in Teva Pharmaceutical Industries by 20.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 7,355,669 shares of the company’s stock valued at $291,284,000 after purchasing an additional 1,226,429 shares during the last quarter. Kranot Hishtalmut Le Morim Tichoniim Havera Menahelet LTD acquired a new stake in Teva Pharmaceutical Industries in the second quarter valued at approximately $33,799,000. Finally, Public Sector Pension Investment Board boosted its position in Teva Pharmaceutical Industries by 85.1% in the third quarter. Public Sector Pension Investment Board now owns 1,239,667 shares of the company’s stock valued at $50,913,000 after buying an additional 570,100 shares in the last quarter. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Latest Teva Pharmaceutical Industries News

These are some of the TEVA news items that stood out recently:

  • Positive Sentiment: Barclays raised its price target to $50 from $47 and maintained an Overweight rating. Argus also raised its target to $50 and reaffirmed a Buy rating, while HC Wainwright maintained its Buy rating. Barclays analyst action Argus forecast HC Wainwright rating
  • Neutral Sentiment: Teva said its R&D strategy, priorities and commitments remain unchanged, including its goal of $6–7 billion in innovative-medicines revenue by 2030. David Gardiner will lead the transition while the company searches for a permanent successor. Teva leadership announcement
  • Negative Sentiment: Executive Vice President of Global R&D and Chief Medical Officer Eric Hughes is leaving for an opportunity outside Teva. His departure may unsettle investors given the importance of R&D execution to the company’s growth strategy, despite his planned support during the transition. R&D leadership transition report

About Teva Pharmaceutical Industries

(Get Free Report)

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.

Further Reading

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.